13F Pro Quality Score

30.5/100

Rank #2,354 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

30.0/100

Profitability

30.0/100

Balance Sheet

27.6/100

Earnings Quality

30.0/100

Free Cash Flow

30.0/100

Institutional Flow

26.0/100

Revenue Scale

30.0/100

Dilution Risk

50.5/100

TFX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for TELEFLEX INC (TFX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TFX at 30.5/100 on a 32-signal composite quality model, placing it at rank #2,354 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (26.0) and balance sheet strength (27.6), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), TELEFLEX INC reports quarterly revenue of $548.3M, net income of $-8.2M, free cash flow of $27.9M. Top institutional holders of TFX by reported 13-F value include BlackRock,, JANUS HENDERSON GROUP PLC, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. TFX trades on the NYSE exchange and files with the SEC under CIK 96943. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TFX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TELEFLEX INC directly from SEC EDGAR. TELEFLEX INC's 13F Pro composite quality score has ranged between 30 and 63 since 2021, currently 30.5 — a declining long-term trajectory across 28 quarterly and live scoring snapshots.

Fun facts about TELEFLEX INC

Quirks, history, and lore behind TFX — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. medical device company · mid-cap · listed on the NYSE · headquartered in Pennsylvania.
  • 2
    The Numbers
    Annual revenue in the range of roughly $3 billion, with products sold to hospitals and clinicians in over 100 countries.
  • 3
    The History
    Founded in the 1940s, it spent decades as a diversified industrial company before pivoting hard into single-use medical devices — catheters, introducers, and all things vascular.
  • 4
    The Secret
    Its bread and butter is critical care and surgical access — the unglamorous but essential gear that keeps patients alive during procedures, like laryngoscopes and chest drainage systems.
  • 5
    The Lore
    Its UroLift system — a minimally invasive treatment for enlarged prostates — became one of its fastest-growing product lines and a genuine urologist favorite.
  • 6
    The Giveaway
    The ticker is three letters that sound like a phone company, but this Wayne, Pennsylvania firm is all about vascular access, anesthesia, and surgical devices — and that UroLift is hard to forget.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$548.3M

Net Income

Q1 2026

$-8.2M

Free Cash Flow

Q1 2026

$27.9M

D/E Ratio

Q1 2026

0.85

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+16.4% YoY
$1.99BFY 2025
FY21 $2.81BFY22 $2.79BFY23 $1.71BFY25 $1.99B

Net Income

-354.2% YoY
$-905.6MFY 2025
FY21 $485.4MFY22 $363.1MFY23 $356.3MFY25 $-905.6M

Operating Income

-54.2% YoY
$118.4MFY 2025
FY21 $628.1MFY22 $499.7MFY23 $258.7MFY25 $118.4M

EPS (Diluted)

-368.9% YoY
$-20.25FY 2025
FY21 $10.23FY22 $7.68FY23 $7.53FY25 $-20.25

Total Assets

-7.8% YoY
$6.95BFY 2025
FY21 $6.87BFY22 $6.93BFY23 $7.53BFY25 $6.95B

Total Debt

+42.8% YoY
$2.84BFY 2025
FY21 $2.07BFY22 $1.89BFY23 $1.99BFY25 $2.84B

AI Insight: TFX Financial Trends

Debt surged 52% from Q2 2024 to Q3 2025 while cumulative net losses since Q4 2024 have eroded equity by roughly $1.5B, signaling a materially stressed balance sheet.

Total debt climbed from $1,718M in Q2 2024 to $2,872M in Q3 2025, a 67% increase in five quarters.

Equity deteriorated from $4,559M in Q2 2024 to $3,084M in Q1 2026, a $1,475M decline.

Revenue dropped sharply to $548M in Q1 2026 from $913M in Q3 2025, the lowest quarterly figure in the dataset.

Operating income recovered to $246M in Q4 2025 and $20M in Q1 2026 after a $-409M operating loss in Q3 2025.

Net losses in Q3 2025 ($-409M) and Q4 2025 ($-714M) suggest large impairment or restructuring charges — magnitude and recurrence warrant scrutiny.

Debt fell modestly from $2,872M in Q3 2025 to $2,617M in Q1 2026; whether deleveraging continues is a key inflection to monitor.

Q1 2026 revenue of $548M is the weakest in the dataset — confirm whether this reflects divestitures, seasonality, or demand deterioration.

AI Insight: TFX Ratio Trends

Massive impairment charges in Q3 2025 and Q4 2025 have cratered TFX's returns, with TTM ROE at -32.7% and ROIC near zero despite a modest Q1 2026 operating margin recovery to 3.7%.

Operating margin collapsed from 19.9% in Q2 2025 to -44.8% in Q3 2025, driven by a large one-off charge, then partially recovered to 3.7% in Q1 2026.

ROIC swung from 9.8% in Q2 2025 to -24.4% in Q3 2025 and sits at just 1.4% in Q1 2026, reflecting severely impaired capital productivity.

Leverage has risen steadily: D/E expanded from 0.38 in Q2 2024 to 0.85 in Q1 2026, tightening the balance sheet amid earnings weakness.

Net profit margin turned slightly negative at -1.5% in Q1 2026, a fragile improvement from -44.8% in Q3 2025 but still below pre-impairment levels.

Whether Q3 2025 and Q4 2025 charges are truly non-recurring — sustained sub-5% operating margins would signal structural deterioration, not a one-off.

D/E at 0.85 is more than double the Q2 2024 level of 0.38; rising leverage alongside negative ROE raises refinancing and covenant risk.

Q1 2026 operating margin recovery to 3.7% is encouraging but far below the 17–20% range seen in Q1–Q2 2025; pace of normalization is critical.

Get alerted when TFX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TELEFLEX INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of TFX

Put TFX on your watchlist

Track score changes the day TELEFLEX INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is TFX a good stock to buy?

13F Pro's AI-powered analysis of TELEFLEX INC (TFX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TFX are available on the TFX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TFX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TFX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TELEFLEX INC's investment landscape.